

# EUROPEAN INNOVATION & PRNDs

POVERTY-RELATED & NEGLECTED DISEASES



## PRNDs\*: THE GLOBAL HEALTH BURDEN

PRNDs such as HIV and AIDS, malaria, tuberculosis (TB) and sleeping sickness - as well as lesser-known worm and parasitic diseases - affect people living in some of the world's poorest countries. As a result, there is little commercial incentive to develop products to address them.

**1 BILLION**  
PEOPLE AFFECTED  
BY PRNDs  
GLOBALLY<sup>1</sup>




**6 MILLION**  
ANNUAL DEATHS  
FROM PRNDs  
WORLDWIDE<sup>2</sup>




**361 MILLION**  
YEARS OF HEALTHY  
& PRODUCTIVE LIFE  
LOST GLOBALLY<sup>2</sup>



## PRNDs: A CONTINUING BURDEN IN THE EU



## R&D: LACK OF ESSENTIAL MEDICAL INTERVENTIONS




Improving the health of the world's poorest populations needs new and improved safe, effective, affordable and accessible tools. In the absence of a viable commercial market, R&D investment by governments and philanthropic organisations is critical to save lives and support healthy communities, both in low- and middle-income countries, and in Europe.

## EU PUBLIC INVESTMENT IN PRND R&D:

€2.1 BILLION (2007-2012)



RETURN ON INVESTMENT:  
66 CENTS OF EACH EURO OF EU  
INVESTMENT IN PRNDs RESEARCH  
IS SPENT WITHIN THE EU.



All figures are adjusted for inflation and reported in 2012 euros

\* In this paper, PRNDs refer to the 31 neglected diseases that are within the scope of the G-FINDER survey: HIV/AIDS, malaria, TB, kinetoplastids, diarrhoeal diseases, salmonella infections, dengue, helminth infections, bacterial pneumonia and meningitis, leprosy, Buruli ulcer, trachoma and rheumatic fever

\*\* European Commission - Directorate General for Development Cooperation (DG DEVCO) and Directorate General for Research and Innovation (DG RTD)



## INNOVATION: MAKING A DIFFERENCE IN LOW AND MIDDLE INCOME COUNTRIES



Carl Zeiss MicroImaging GmbH (Germany) developed a test that detects **10% more TB cases** and is **four times faster** than the current TB test.



Sigma-Tau (Italy) worked with Oxford University (UK) and Medicines for Malaria Venture, a Swiss-based non-profit drug developer, to develop Eurartesim, a **fast-acting, easy-dosage new drug to treat malaria**.



**MANY WITH EU INPUT**

## EU FUNDING FOR GLOBAL HEALTH R&D: INSTRUMENTS FOR 2014-2023

### DIRECT SUPPORT TO GH R&D FOR PRNDS

European & Developing countries Clinical Trials Partnership (EDCTP) 2014-2023

**€1.3 BILLION**

(€683 million from the EU matched by at least €683 million from Participating States)

Clinical research for HIV&AIDS, malaria, TB and neglected tropical diseases focusing on Sub-Saharan Africa. The EU contribution comes out of the Horizon 2020 budget for the "health, demographic change and well-being" challenge.

Horizon 2020 work programme of DG Research & Innovation for health, demographic change & well-being for 2014 and 2015 indicative budget of

**€45 MILLION**

for HIV and TB vaccine calls

### POTENTIAL COMPLEMENTARY SUPPORT TO GLOBAL HEALTH, INNOVATION OR WORK ON PRNDS

Horizon 2020

European Research Council 2014-2020  
With a panel on Immunity and Infection

Innovative Medicines Initiative (IMI) 2014-2024  
Including for antimicrobial resistance, respiratory diseases & vaccines

Development Cooperation Instrument (DCI)


Global Public Goods and Challenges 2014-2020  
With support to GAVI Alliance, Global Fund to fight HIV and AIDS, malaria and TB, support to WHO for translational research, Pilot projects/ preparatory actions for e.g. R&D priority mapping, capacity building of national regulatory authorities

Pan African Programme 2014-2020  
Including support to Science, Technology and Innovation area of cooperation of Joint Africa-EU Strategy and African Research grants

European Development Fund (EDF)

Intra-ACP Fund 2014-2020  
Supporting GAVI Alliance, Global Fund to fight HIV and AIDS, malaria and TB, Water Sanitation and Hygiene projects

## R&D FOR PRNDS: ATTRACTING INVESTMENT FOR THE EU



**EVERY €1 INVESTED BY EUROPEAN GOVERNMENTS INTO PRND R&D BETWEEN 2007 & 2012...**

**...BROUGHT AN ADDITIONAL €1.47 IN INVESTMENT FROM OUTSIDE INTO EUROPE**

- US National Institutes of Health. FAQ about Neglected Diseases. National Center for Advancing Translational Sciences. 2012 [cited 2014 June 5]. Available from: <http://www.ncats.nih.gov/about/faq/neglected/neglected-faq.html>
- Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2010 (GBD 2010) Results by Cause and by Region 1990-2010. 2013 [cited 2014 June 5]. Available from: <http://ghdx.healthmetricsandevaluation.org/global-burden-disease-study-2010-gbd-2010-data-downloads>
- European Centre for Disease Prevention and Control, World Health Organization. Surveillance Report: Tuberculosis surveillance and monitoring in Europe 2014. 2014 [cited 2014 June 5]. Available from: <http://www.ecdc.europa.eu/en/publications/Publications/tuberculosis-surveillance-monitoring-Europe-2014.pdf>
- European Centre for Disease Prevention and Control, World Health Organization. Surveillance Report: HIV/AIDS surveillance in Europe 2012. 2013 [cited 2014 June 5]. Stockholm; 2013. Available from: <http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-report-2012-20131127.pdf>
- Médecins Sans Frontières. Running out of breath? TB care in the 21st century. 2005 [cited 2014 June 5]. Switzerland; 2005 p. 23. Available from: [http://www.msfaccess.org/sites/default/files/MSF\\_assets/TB/Docs/TTB\\_report\\_RunningOutOfBreath\\_21stCentury\\_ENG\\_2005.pdf](http://www.msfaccess.org/sites/default/files/MSF_assets/TB/Docs/TTB_report_RunningOutOfBreath_21stCentury_ENG_2005.pdf)



**DSW**

DSW (Deutsche Stiftung Weltbevölkerung)  
Place du Luxembourg 2/3  
1050 Brussels  
Belgium  
Tel: +32 2 504 90 60  
E-mail: [brussels@dsw.org](mailto:brussels@dsw.org)



[www.dsw.org](http://www.dsw.org)



DSWDeutscheStiftungWeltbevölkerung



@dsw\_worldwide

IN COLLABORATION WITH

